This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ohtsu, A. Articles by Saijo, N. Search for Related Content PubMed PubMed Citation Articles by Ohtsu, A. Articles by Saijo, N. Social Bookmarking                            What's this?

Disparities in Gastric Cancer Chemotherapy Between the East and West

Atsushi Ohtsu, Shigeaki Yoshida, Nagahiro Saijo

From the Division of Gastrointestinal Oncology/Digestive Endoscopy and Division of Thoracic Oncology, National Cancer Center Hospital E, Kashiwanoha, Kashiwa, Japan

Address reprint requests to Atsushi Ohtsu, MD, Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital E, 6-5-1, Kashiwanoha, Kashiwa, 277-8577 Japan, e-mail: aohtsu{at}east.ncc.go.jp

There are still remarkable disparities in the treatment of gastric cancer between the East and West. Treatment outcomes for this disease have improved in Japan due to early detection and surgical resection with systematic node dissections, such as D2, whereas gastric cancer remains a virulent disease in Western countries. Differences in the types of surgery and their outcomes affect how adjuvant trials are conducted and interpreted. Recent Western randomized trials demonstrated the significant survival benefit of adjuvant chemoradiotherapy or intensive combination chemotherapy. However, baseline surgical quality and outcomes were quite different from those in Japan, and Japanese surgical/medical oncologists have not accepted the Western results. Several disparities are also evident in the results of chemotherapy trials for advanced gastric cancer. Although similar results were obtained with randomized studies using older regimens, the interpretation of the results differed between Japan and other countries. A combination of cisplatin and fluorouracil was used as the reference arm in ongoing randomized trials in most countries, whereas single-agent fluorouracil or S-1 alone was used in Japanese trials. Two triplet regimens have already demonstrated significant prolongation of survival in Western studies. However, these benefits seem to be marginal and these regimens may be replaced by newer regimens, which will soon be available in Europe and Asia, where a total of 2,600 patients have been accrued. Although these disparities between regions must be overcome, it is time for both Eastern and Western investigators to pursue further benefits by incorporating new agents into treatment regimens.

Supported in part by a Grant-in-Aid No. 17S-3 from the Ministry of Health, Labor, and Welfare, Japan.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. C. TSAMANDAS, D. KARDAMAKIS, P. TSIAMALOS, A. LIAVA, V. TZELEPI, V. VASSILIOU, T. PETSAS, K. VAGENAS, V. ZOLOTA, and C. D. SCOPA The Potential Role of Bcl-2 Expression, Apoptosis and Cell Proliferation (Ki-67 Expression) in Cases of Gastric Carcinoma and Correlation with Classic Prognostic Factors and Patient Outcome Anticancer Res, February 1, 2009; 29(2): 703 - 709. [Abstract] [Full Text] [PDF]

				B. Badgwell, J. N. Cormier, Y. Xing, J. Yao, D. Bose, S. Krishnan, P. Pisters, B. Feig, and P. Mansfield Attempted Salvage Resection for Recurrent Gastric or Gastroesophageal Cancer Ann. Surg. Oncol., January 1, 2009; 16(1): 42 - 50. [Abstract] [Full Text] [PDF]

				N. I. Khushalani Cancer of the Esophagus and Stomach Mayo Clin. Proc., June 1, 2008; 83(6): 712 - 722. [Abstract] [Full Text] [PDF]

				J. Matsubara, Y. Yamada, Y. Hirashima, D. Takahari, N. T. Okita, K. Kato, T. Hamaguchi, K. Shirao, Y. Shimada, and T. Shimoda Impact of Insulin-Like Growth Factor Type 1 Receptor, Epidermal Growth Factor Receptor, and HER2 Expressions on Outcomes of Patients with Gastric Cancer Clin. Cancer Res., May 15, 2008; 14(10): 3022 - 3029. [Abstract] [Full Text] [PDF]

				S. H. Park, E. Nam, J. Park, E. K. Cho, D. B. Shin, J. H. Lee, W. K. Lee, M. Chung, and S. I. Lee Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer Ann. Onc., April 1, 2008; 19(4): 729 - 733. [Abstract] [Full Text] [PDF]

				T. D. Yan, D. Black, P. H. Sugarbaker, J. Zhu, Y. Yonemura, G. Petrou, and D. L. Morris A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer Ann. Surg. Oncol., October 1, 2007; 14(10): 2702 - 2713. [Abstract] [Full Text] [PDF]

				O. I. Olopade, G. Schwartsmann, N. Saijo, and C. R. Thomas Jr Disparities in Cancer Care: A Worldwide Perspective and Roadmap for Change J. Clin. Oncol., May 10, 2006; 24(14): 2135 - 2136. [Full Text] [PDF]